Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BP-C2 Dose Finding in Prostate Cancer
NCT04186585Phase 1Recruiting
- Sponsor
- Meddoc
- Start
- Apr 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BP-C2 in prostate cancer (PCa), sponsored by Meddoc. Primary endpoints: Maximum Common Terminology Criteria for Adverse Events Score at Week 8 and Sum of Common Terminology Criteria for Adverse Events Scores at Week 8. Started Apr 2023; status: recruiting.
02
Drugs
BP-C2
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04186585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04186585.